A different approach to women’s health technology
Women’s health technology has traditionally focused on helping individuals track symptoms, reproductive cycles, and other personal health information.
A growing group of innovators is exploring how connected diagnostics, software, and artificial intelligence might support more comprehensive approaches to care.
South Korean femtech company Vespexx is among the businesses developing technology in this area.
On October 22, 2026, Vespexx announced that its Soonr platform had been selected as a finalist for the Digital Health Hub Foundation’s 2026 Digital Health & AI Awards.
The company is competing in the Rising Star track within the Women’s & Family Health category.
The recognition places Vespexx among the competition’s finalists, with winners scheduled to be announced on November 16, 2026.
What is Soonr?
Soonr is a preconception health platform designed to involve both partners in fertility planning.
The application allows couples to connect their accounts and share relevant information, including cycle-tracking data and health-related updates.
According to Vespexx, the platform can integrate information from connected at-home hormone-testing technology.
The company describes its approach as an effort to make preconception planning more collaborative.
Rather than positioning fertility tracking solely as an individual responsibility, Soonr is designed to provide both partners with access to information that may help them participate in the process.
Combining diagnostics and software
Vespexx operates at the intersection of reproductive health, digital products, and connected diagnostic technology.
Its Soonr platform is associated with hormone-testing technology from Surearly SMART.
Vespexx describes its approach as integrating health information, diagnostics, and AI-enabled insights.
However, company-reported product capabilities should not be interpreted as independent evidence of clinical effectiveness.
Similarly, a medical device being FDA-listed or registered does not necessarily mean that every associated application, feature, or health claim has received FDA approval.
People making reproductive health decisions should consult qualified healthcare professionals.
The leadership behind the innovation
Vespexx is led by co-CEOs Scarlett Joowon Jung and Mijin Son.
The company has also participated in South Korea’s 2026 Global ICT Future Unicorn program, an initiative supporting technology companies with international growth potential.
Its current expansion efforts include the United States.
For women interested in STEM entrepreneurship, Vespexx illustrates how businesses can emerge from the intersection of healthcare needs, consumer experience, diagnostic technology, and software development.
It also demonstrates the importance of identifying problems that existing products may not fully address.
Why this recognition matters
Digital health awards can provide emerging companies with exposure to industry leaders, investors, and potential partners.
They do not, by themselves, establish product effectiveness or commercial success.
For Vespexx, the finalist recognition offers an opportunity to present its approach to a broader healthcare innovation audience.
The company’s longer-term impact will depend on the performance, adoption, safety, and usefulness of its technology.
Looking ahead
The Digital Health Hub Foundation’s awards ceremony is scheduled for November 16, 2026, during HLTH USA in Las Vegas.
Vespexx has been named a finalist, but the award outcome remains pending.
For the broader women’s health technology sector, the announcement highlights continued interest in products that combine software, diagnostics, and patient-centered design.
It also reinforces an important opportunity for women in STEM: helping shape how emerging technologies respond to health needs that have historically received insufficient attention.
Sources and further reading
Discover more from Fems in STEM
Subscribe to get the latest posts sent to your email.
